“Nudges” from electronic health records could improve the implementation of tobacco use treatment almost three-fold over standard care.

CHOP has treated its 500th patient with CAR T-cell immunotherapy, a “living drug” that harnesses the power of a patient’s own immune system to fight cancer.

Children’s Hospital of Philadelphia (CHOP) announced it has received $1 million from Pediatric Cancer Foundation, an organization that has been raising funds for research since 1970 to support doctors and hospitals in an effort to eradicate childhood cancer. The grant will help to fund a planned first-in-human phase 1 clinical trial led by Sarah K. Tasian, MD, which will use a new immunotherapy to target the FLT3 receptor protein in high-risk pediatric leukemias.

This award honors a CHOP employee who has gone above and beyond to make an impact on the lives of children treated in the Division of Oncology.

CHOP researchers have identified a molecule that plays a role in post-translational modification and activation in myeloid cancers, making it a potential therapeutic target.

Collaboration among CHOP, Alex’s Lemonade Stand Foundation, the Pacific Pediatric Neuro-Oncology Consortium, and Children’s Brain Tumor Network paves the way for new collaborative models to accelerate discoveries.

CHOP and UCLA researchers have created a tool that can discover tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets.

Two recent papers from CHOP cancer researchers have advanced the understanding of treatment-resistant pediatric central nervous system tumors.

CHOP researchers have shown that adenovirus proteins use a process called phase separation to coordinate production of viral progeny, which could have broad implications.

Levy traveled from Brazil and participated in a clinical trial for an oral drug that targets an NTRK gene fusion that drives cancer-cell growth.